Back to Newsroom

New England Journal of Medicine Article Supports Importance of Follow-up Diagnostic Testing Following Positive Noninvasive Prenatal Screening Test

IRVINE, Calif., April 10, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based diagnostic services for prenatal, postnatal, and pre-implantation genetic testing today announced that an article and a letter to the editor published online on April 1, 2015 in the New England Journal of Medicine support the need for follow-up confirmatory diagnostic testing following a positive noninvasive prenatal screening test (NIPT) result.
Click here to read more